Rate of hepatitis C reinfection after successful direct-acting antivirals treatment among people who inject drugs in Spain : the LIVERate study
Chacón García, Fernando (Merck Sharp and Dohme (Madrid))
Morano, Luis (Hospital Álvaro Cunqueiro (Vigo))
Navarro, Jordi (Hospital Universitari Vall d'Hebron)
Granados, Rafael (Hospital Universitario de Gran Canaria Dr. Negrín)
Llibre, Josep M. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Ryan, Pablo (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM))
Aldámiz-Echevarria, Teresa (Hospital General Universitario Gregorio Marañón)
Martín Carbonero, Luz (Hospital Universitario La Paz (Madrid))
Puigvehí, Marc (Hospital del Mar (Barcelona, Catalunya))
Clotet-Codina, Imma (Merck Sharp and Dohme (Madrid))
Sanchez-Vega, Nuria (Merck Sharp and Dohme (Madrid))
Vacas, Enrique (Merck Sharp and Dohme (Madrid))
Rincón, Oscar (Merck Sharp and Dohme (Madrid))
Berenguer, Juan (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM))
Crespo, Javier (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria))
Roncero, Carlos (European University Miguel de Cervantes)

Data:	2024
Resum:	Background: Hepatitis C virus (HCV) reinfection following successful treatment threatens the achievement of HCV elimination. The primary aim of this study is to assess reinfection rate three years after sustained virologic response (SVR) in people who inject drugs (PWID) that are on opioid agonist treatment (OAT) who underwent anti-HCV treatment with interferon-free regimens. Methods: Observational, non-interventional, prospective, descriptive study carried out in Spanish tertiary public hospitals between 2017 and 2022. Participants comprised 186 adult HCV infected individuals, 85. 5% males with a mean age (Standard Deviation, SD) of 50. 1 (5. 9). All were enrolled in an OAT program at baseline and had attained SVR 12 weeks after therapy completion with an interferon-free treatment. Baseline data were abstracted from medical chart information collected through the routine clinical practice. Results: The overall rate of HCV reinfection three years after SVR12 among PWID was 1. 2 new cases per 100 person-years of follow-up at a median of 15. 9 months. In the subgroup analyses, those with injection drug practice and without a stable housing had higher reinfection rates. Conclusion: Although PWID in OAT present a low rate of reinfection by HCV after successful treatment, a closer monitoring in the first year and strengthening inter-consultations with services responsible for monitoring addiction in these patients will be crucial to reduce risky behaviors avoiding HCV reinfection.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Publicat a:	BMC public health, Vol. 24 Núm. 1 (december 2024) , p. 3167, ISSN 1471-2458

DOI: 10.1186/s12889-024-20625-3
PMID: 39543579

10 p, 1.4 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Articles de recerca
Articles > Articles publicats